Evaluating the Effects of Adjunctive Aripiprazole on Weight and Metabolic Outcomes in Females

Patients with psychiatric disorders, including depression, anxiety, and schizophrenia, often require antipsychotic medications for symptom management. However, metabolic changes, especially weight gain, are a common and challenging side effect of many antipsychotics. Aripiprazole, an atypical antipsychotic, has shown promise in mitigating this adverse effect when used in combination with other antipsychotic medications.

NCT Number	NCT06590298
Lead Sponsor	Universiti Putra Malaysia
Conditions	Psychosis, Metabolic Syndrome, Weight Gain
Enrollment	600 participants
Start Date	2024-09-15
Primary Completion	2025-03-15 (estimated)
Study Completion	2025-04-10 (estimated)
Updated on ClinicalTrials.gov	2024-09-19